Pfizer (PFE) Rises But Trails Market: What Investors Should Know
Pfizer Options Spot-On: On September 26th, 107.56K Contracts Were Traded, With 2.77 Million Open Interest
Express News | FDA: Patients and Caregivers Should Contact Their Health Care Professional About Stopping Oxbryta and Starting Another Treatment Option
Express News | FDA Is Alerting Patients and Health Care Professionals About Voluntary Withdrawal of Oxbryta From Market Due to Safety Concerns
Fulcrum Therapeutics Swings up 17% on Pfizer Sickle Cell Drug Setback
Fulcrum Therapeutics Potential Winner After Pfizer Pulls Oxbryta -- Market Talk
Micron Reports Q4 Beat, Pfizer Withdraws Oxbryta: Morning Buzz
Pfizer's Strategy Looks Shakier After Sickle-Cell Disappointment -- Barrons.com
Pfizer's Oxbryta Exit May Hasten Trials of Rival Experimental Sickle Cell Drugs, Analysts Say
Time to Order Your Free At-Home Covid Tests. Here's How. -- Barrons.com
EU Regulator Recommends Suspension of Pfizer's Sickle Cell Disease Treatment
Express News | EMA: Chmp Considered That Data From Ongoing EMA Review Raise Serious Concerns About Safety of Oxbryta Due to Increased Uncertainties
Express News | EMA Recommends Suspension of Sickle Cell Disease Medicine Oxbryta
Pfizer Recalls All of Its Sickle Cell Disease Treatment Over Safety Concerns
Pfizer Voluntarily Withdraws Sickle Cell Disease Treatment Oxbryta From Global Market Due To Painful Disease Complication, Deaths
Pfizer Withdrawal of Oxbryta Raises Questions, Sends Fulcrum Stock Higher
Express News | Agios Pharmaceuticals Shares up 5% After Rival Pfizer Withdraws Sickle Cell Disease Treatment
Leerink Sees Little Impact to Genetic Medicines From Pfizer's Oxbryta Withdrawal
Express News | Pfizer Shares Fall 1% After Withdrawing Sickle Cell Disease Treatment on Risk of Complication, Death
Market Chatter: Pfizer CEO Reports Slow Progress on Plan to Sell Drugs to Poor Countries